

Contents

1	Diabetic Complications: Pathobiology of Hyperglycemic Damage and Potential Impact on Treatment	1
	M. Brownlee	
	Introduction	1
	How does Hyperglycemia Cause Microvascular Damage?	1
	Macrovascular Damage: The Role of Free Fatty Acids	3
	The Long-Term Influence of Hyperglycemic Memory	4
	Potential Therapeutic Approaches: The Role of Transketolase Activation	5
	Conclusions	6
2	Thiamine and Benfotiamine Therapy for the Prevention of Diabetic Nephropathy	9
	P. J. Thornalley, N. Rabbani	
	Introduction	9
	Effect of Thiamine and Benfotiamine on Cell Function in Hyperglycemia	10
	Prevention of Nephropathy in Experimental Diabetes	11
	Can Thiamine Prevent Diabetic Nephropathy in Type 2 Diabetes?	14
	Conclusions	15
3	Thiamine Deficiency and Renal Function in Diabetes	18
	N. Rabbani, P. J. Thornalley	
	Introduction	18
	Assessment of Thiamine Sufficiency: The "Thiamine Effect"	18
	Thiamine Deficiency in Experimental and Clinical Diabetes	18
	The Role of Thiamine Transporters	21
	Impaired Renal Re-uptake of Thiamine in Diabetes: The Link to the Hexosamine Pathway	21
	Thiamine Status and Renal Function	23
	Conclusions	24

4 Protective Effects of Thiamine and Benfotiamine on Retinal Endothelial Cells and Pericytes in High-Glucose Conditions: Relevance to Diabetic Retinopathy 26

E. Beltramo

Introduction	26	Diabetic Retinopathy: The Impact of the Major Pathways of Glycolysis . . .	30
Effects of Thiamine and Benfotiamine in Endothelial Cells	27	Establishment of an Immortalized Human Retinal Pericyte Line	33
Effects of Thiamine and Benfotiamine in Retinal Pericytes	28	Conclusions	34
Prevention of Increased Apoptosis and AGE Production by Thiamine and Benfotiamine	30		

5 Diabetic Neuropathy: Clinical Problems and Potential Therapeutic Approaches 36

P. Kempler

Introduction	36	Aldose Reductase Inhibitors	39
Distal Symmetrical Polyneuropathy: Symptoms and Diagnosis	36	PKC inhibitors	39
Therapy for Diabetic Neuropathy	37	Benfotiamine	39
Pathogenetically Oriented Treatment	38	α -Lipoic Acid	41
Glycemic Control and Management of Risk Factors	38	Symptomatic Treatment of Diabetic Polyneuropathy	42
		Conclusions	42

6 Treatment of Diabetic Polyneuropathy with Benfotiamine: Results of the BENDIP Study . 45

H. Stracke

Introduction	45	Results	49
Characteristics of Benfotiamine	46	Potential and Limitations	50
The BENDIP Study	47	Conclusions	51
Design	47		

7 Prevention of Postprandial Endothelial Dysfunction 54

A. Stirban

Introduction	54	AGEs, Endothelial Dysfunction, and Oxidative Stress in Diabetes	56
Endothelial Dysfunction	54	Is There a Direct Antioxidative Effect of Benfotiamine?	60
Advanced Glycation Endproducts	55	Conclusions	62
Synergism of Exogeneous and Endogeneous AGEs	56		

Index	65
------------------------	-----------